Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1117568 in Adults With Bipolar I Disorder Experiencing a Manic Episode
NCT07288320Phase 2Recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Dec 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar I disorder comparing NBI-1117568 with Placebo (2 arms). Primary endpoint: Young Mania Rating Scale Total Score at 21 days. Started Dec 2025; status: recruiting.
02
Drugs
direclidine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT07288320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288320.